CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −8,827 | $210.99 | $1.9M | 427,024 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −5,009 | $211.84 | $1.1M | 422,015 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −1,363 | $212.85 | $290K | 420,652 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −2,190 | $213.85 | $468K | 418,462 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −1,804 | $214.68 | $387K | 416,658 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −375 | $216.08 | $81K | 416,283 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −721 | $216.98 | $156K | 415,562 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −1,100 | $217.86 | $240K | 414,462 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −1,000 | $218.99 | $219K | 413,462 |
| 2024-05-14 | CRAVES FRED B Director | Sale 10b5-1 | −100 | $219.90 | $22K | 413,362 |
| 2024-05-14 | CRAVES FRED B Director | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2024-05-14 | CRAVES FRED B Director | Option exercise · Stock Option (right to buy) 10b5-1 | −12,489 | 0 | ||
| 2024-04-08 | Taub Rebecca Pres., R&D, and CMO | Option exercise 10b5-1 | +2,676 | $9.45 | $25K | 461,675 |
| 2024-04-08 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −224 | $243.25 | $54K | 461,451 |
| 2024-04-08 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −945 | $244.79 | $231K | 460,506 |
| 2024-04-08 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −300 | $245.69 | $74K | 460,206 |
| 2024-04-08 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −600 | $246.98 | $148K | 459,606 |
| 2024-04-08 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −407 | $247.76 | $101K | 459,199 |
| 2024-04-08 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −200 | $248.58 | $50K | 458,999 |
| 2024-04-08 | Taub Rebecca Pres., R&D, and CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,676 | 76,564 |
Page 30 of 82 · 1,629 trades